The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

If you should have questions about the protocol/treatment regimen, please call (404)-851-8238

Leukemia/Lymphoma - Updated October 15, 2017
  • NSH 1032 – A phase I/Ib study of ipilimumab or nivolumab in patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation
  • NSH 1095 – Collection of Bone Marrow and Peripheral Blood (PB) samples from patients with leukemia and PB from the BM donors (BMD) to identify Leukemia-Specific Antigens (LSA) and Graft Versus Host Disease Antigens (GVHDA) for use in cellular immunotherapy
  • NSH 1099 – E1910 Phase 3 randomized trial of blinatumomab for newly diagnosed BCR-ABL negative B-ALL in adults
  • NSH 1115 – A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies
  • NSH 1144 – A Phase II, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
  • NSH 1164 – A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb14045 in Patients with CD123-Expressing Hematological Malignancies
  • NSH 1165 – Phase 1, Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
  • NSH 1169 – A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
  • NSH-1170 – A Phase 1, multicenter, open-label study of JCAR017, CD19-targeted chimeric antigen receptor (CAR) T cells, in relapsed and refractory (R/R) B-cell non-Hodgkin Lymphoma
  • C-250 – A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML)
  • C-262 – A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory AML with FLT3 Mutation